cyrilzakka/clinical-trials huggingface dataset:
Acceptance of Telemedicine in Dermatology Patients, Physicians and Medical Staff

This study is to investigate the current use and intention to use of teledermatology in Swiss dermatology patients, dermatologists, other physicians and medical staff.

Telemedicine, the use of telecommunication and information technology to provide clinical health care from a distance, has become an increasing role in basic medical care internationally. Telemedicine is particularly suitable for skin diseases. In order to improve the use of evidence-based telemedicine, the Swiss patients' preferences regarding teledermatology versus face-to-face consultations and the patients' and physicians' determinants of acceptance for teledermatology are investigated in this study. Dermatology patients are asked to complete a newly-created 21-items-survey; Swiss dermatologists, other physicians and medical staff on telemedicine will complete a similar newly-created, 23-items-questionnaire. A descriptive statistical analysis (e.g. gender, age, place of residence (city or country), waiting time) will be performed.

Eligibility Criteria:
Inclusion Criteria:

* patients treated in the Department of Dermatology of the Cantonal Hospital Aarau and the University Hospitals Basel and Zürich
* dermatologists, other physicians and medical staff of the Department of Dermatology of the Cantonal Hospital Aarau and the University Hospitals Basel and Zürich

Exclusion Criteria:

-
Development of a Quality of Life Measurement Scale in Hereditary Haemorrhagic Telangiectasia (HHT) Disease.

Hereditary Haemorrhagic Telangiectasia (HHT) is a rare inherited genetic disease of autosomal dominant inheritance with a prevalence of 1/6000. It is manifested by haemorrhages, mucocutaneous telangiectasias and visceral arteriovenous malformations. These symptoms significantly affect the daily lives of patients, their social relationships and their working lives.

HAS (Haute Autorité de Santé) national recommendations focus on assessing and improving the quality of life (QOL) of patients. Many scales for measuring QOL exist but they are most often general and therefore have the disadvantage of not taking into account the particularities of pathologies and their symptoms and do not allow to have a precise vision of their impact on QOL.

It is important to be able to evaluate this impact, to determine its nature and to quantify it so that health professional can adapt their proposal for the management of HHT patients. And only the development of a specific and validated QOL measurement scale will allow them to access this information.

The aim of this study is to develop a scale of measurement of quality of life in HHT disease and to validate it, a scale specific to HHT, simple and fast to fill by the patients themselves.


Eligibility Criteria:
Inclusion Criteria:

* over 18 years
* able to read French
* with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology
* who received the information and did not object to participate in the study

Exclusion Criteria:

* None
Antialbuminuric Effects of Valsartan and Lisinopril

Title: Antialbuminuric effect of valsartan, lisinopril and valsartan versus lisinopril in non-diabetic and diabetic renal disease: a randomized (3:3:1), open label, parallel group, 20 weeks follow-up.

Objective: To evaluate the antialbuminuric effect of high doses of valsartan vs lisinopril vs combo treatment in non-diabetic and diabetic patients.

Hypothesis: Combo treatment reduces microalbuminuria and the albumin/creatinine ratio more than monotherapies..

Design: Multicentric, randomized, open label, parallel group, active controlled.

Dose / regimen: Valsartan 320 vs Lisinopril 40 vs Valsartan/lisinopril 160/20

Primary Endpoint: Antialbuminuric effect of valsartan 320 mg, lisinopril and valsartan versus lisinopril 40 mg in non-diabetic and diabetic renal disease following 5 months of follow-up. Description % of change in albuminuria from baseline at 20 weeks.

Secondary Endpoint : To investigate the effect of 5 months treatment with valsartan,lisinopril and valsartan versus lisinopril in GFR (Cl creatinine), also to investigate the effect of 5 months treatment with valsartan, lisinopril and valsartan plus lisinopril on blood pressure and the effect on left ventricular mass index using electrocardiogram and Cornell-Sokolow method.


Eligibility Criteria:
Inclusion Criteria:

* Male or female outpatients aged 40-75 years,
* Chronic nephropathy, as defined by a serum creatinine concentration of \> 1.3 mg/dL or calculated glomerular filtration rate of \> 30 mL/min/1.73 m2.
* Persistent albuminuria, as defined by urinary albumin excretion exceeding 20 mg/ 24 h but not \> 1000 mg/ 24h. (for a minimum of three months).
* Hypertensive patients not adequately controlled with or without treatment (controlled: \<130/80 mmHg).
* Written informed consent to participate in the study prior to any study procedures.

Exclusion Criteria:

* Immediate need for renal replacement therapy.
* Treatment resistant oedema or nephrotic syndrome.
* Need for treatment with corticosteroids, non-steroidal antiinflammatory drugs, or immunosuppressive drugs.
* Albuminuria greater than 1000mg /24h and or less than 20mg/24h.
* Total cholesterol \< 135mg/dl or not need for statins treatment.
* Renovascular hypertension
* Malignant hypertension
* MI, cerebrovascular accident within last year, severe peripheral vascular disease, CHF, chronic hepatic disease.
* Angiotensin converting enzyme inhibitors and angiotensin II receptors blockers within one month prior to randomization.
* A serum creatinine concentration \>265 umol/L
DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe this drug. The purpose of this study is to determine if darusentan is effective in reducing systolic blood pressure in subjects with resistant systolic hypertension, despite treatment with full doses of three or more antihypertensive drugs, including a diuretic.


Eligibility Criteria:
Inclusion Criteria:

* Subjects who are competent to provide written consent
* Aged 35 to 80 years
* Subjects with diabetes and/or chronic kidney disease must have a mean systolic blood pressure ≥130 mmHg
* All other subjects must have a mean systolic blood pressure ≥140 mmHg
* Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic
* Female subjects of non-childbearing potential (i.e., post-menopausal for at lest 2 years; surgically sterile)

Exclusion Criteria:

* Average sitting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg
* Serum ALT or AST \>2 x the upper limit of the normal range (ULN)
* Subjects who have experienced myocardial infarction, unstable angina pectoris, or a cerebrovascular accident (CVA) within 6 month; or sick sinus syndrome or second or third degree atrioventricular block, atrial fibrillation or recurrent atrial tachyarrhythmia, recurrent ventricular tachycardia, or symptomatic bradycardia
* Implanted pacemakers or implanted cardioverter defibrillator (ICD)
* Symptomatic congestive heart failure requiring treatment
* Hemodynamically significant valvular heart disease
* Type I diabetes mellitus
* Hemodialysis or peritoneal dialysis; or history of renal transplant
* Diagnosis or recurrence of malignancy within the past 3 years
* Sleep apnea, unless a recent sleep study demonstrates arterial oxygen saturation greater than or equal to 90%
* Subjects who perform alternating shift or night work
* Subjects who have participated in a clinical study involving another investigational drug or device within 4 weeks prior to Screening
Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients

This study will assess and compare the safety and tolerability of inhaled TPI 1020 (repeated nominal doses; 500 μg BID x 6 weeks) versus inhaled budesonide (repeated doses; 800 μg BID x 6 weeks) and a matching placebo. Pharmacodynamic (PD) activity on FEV1, sputum and blood cells and cytokines will also be studied.

A multi-centre, randomized, placebo and active-controlled, 6-week study of inhaled TPI 1020, inhaled budesonide or matching placebo (random allocation of eligible patients to the three treatments at a ratio of 3:3:1), to evaluate the safety, tolerability and pharmacodynamic activity of TPI 1020 in 42 evaluable COPD subjects.

Eligibility Criteria:
Inclusion Criteria:

* Outpatients, male or female, smoker or ex-smoker (who quit at least a year ago) with a smoking history equal or greater than 10 pack years.
* Age between 40 and 80 years old with a diagnosis (for at least 12 months) of mild to moderate COPD

Exclusion Criteria:

* COPD exacerbations indicated by a treatment with oral or systemic glucocorticosteroids and/or hospitalization and/or clinically relevant respiratory infection requiring antibiotics within 3 month of the start of the study.
* Failure to produce a sufficient sputum sample during the screening sputum induction procedure, required for TCC and differential cell count determination.
A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants

The primary objective of this study is to better understand the pathophysiological background of end-of-dose symptoms (EOD) and thereby determine the percentage of participants who develop EOD under natalizumab (NTZ) as an example of interval therapy in MS and to detect specific changes through multimodal analyses, including radiological, blood and digital health measurements, that may be used as potential biomarkers in the future to map EOD.

Participants will additionally be offered to record daily activity and sleep patterns as well as heart rate for the duration of the study.

Eligibility Criteria:
Key Inclusion Criteria:

* Diagnosed Relapsing-Remitting Multiple Sclerosis (RRMS) according to 2017 revised McDonald criteria
* Initiation of treatment with SC NTZ according to summary of product characteristic (SmPC) and in accordance to national guidelines or
* Continuing treatment with IV NTZ
* Owns and be able to handle a smartphone

Key Exclusion Criteria:

* Participants with an acute MS relapse and/or a history of intravenous corticosteroid treatment within past six weeks
* Any comorbidity resulting in an impairment to understand or successfully complete the study such as (but not restricted to) psychiatric comorbidities or dementia
* Diagnosis of primary or secondary progressive MS
* Additional immunosuppression except of natalizumab

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
A Noninvasive Test for Fetal RHD Genotype

The objective of this study is to evaluate the performance of Sequenom's noninvasive test for fetal RHD genotype. The test uses MALDI-TOF mass spectrometry to detect DNA. The study is specifically designed to determine whether RHD typing using free fetal DNA in maternal circulation can accurately predict the neonatal RhD phenotype at birth.

In the United States and Canada, routine obstetrical care includes a blood test to determine the blood type of the mother (ABO and RhD). An antibody screen for anti-red cell antibodies in the mother's serum is also performed.

Postpartum prophylactic treatment of RhD negative women with anti-D immunoglobulin to prevent "RhD Disease", or hemolytic disease of the fetus/newborn, was initiated in the 1960's. In the mid 1980's, the routine administration of antenatal anti-D immunoglobulin became the standard of care as well. Although these treatments have dramatically reduced the incidence of RhD Disease, approximately 40% of all RhD negative pregnancies continue to receive unnecessary injections of antenatal anti-D immunoglobulin.

Genotyping platforms such as MALDI-TOF mass spectrometry allow for precise and sensitive detection of fetal-specific (paternally derived) alleles in maternal plasma. In this study, Sequenom's MassARRAY technology will be used to assess a noninvasive test for fetal RHD genotyping in a clinical setting.

Eligibility Criteria:
Inclusion Criteria:

* Female at least 18 years of age
* RhD negative by serology
* Pregnant at no more than 11-13 weeks gestation confirmed by ultrasound
* Willing to provide signed and dated informed consent
* Able and willing to comply with the protocol

Exclusion Criteria:

* RhD negative women known to be alloimmunized to the RhD antigen
Incidence of POPF in the Resection of the Left Pancreas With RFAT

This study evaluates the impact of the Radiofrequency assisted transection on the rate of postoperative pancreatic fistula (POPF) after performing distal pancreatectomies, central pancreatectomies and pancreatic enucleation

Among the different methods for sealing the remaining pancreas, resection and sealing devices assisted by radiofrequency energy (RF) have been used, both in experimental studies and in clinical trials, in order to try to reduce the POPF rate. One of these devices is the Coolinside®, which is approved for this indication and is currently used in selected cases, at the Hospital del Mar, among other centers.

Although there are several published studies based on similar technology, the existing publications on the use of Coolinside® in the pancreas have been made in rat and pig animal models. In particular, the most recent study published by Dorcaratto et al. compares the Coolinside device vs. the mechanical stapler in porcine model when performing distal pancreatectomies. The results suggest that the Coolinside device was more efficient in the control of the POPF than the stapler with a POPF index of 12% vs. 36%.

Therefore, this study aims to obtain more clinical evidence about the use of Coolinside in pancreatic resections within a clinical context.

Eligibility Criteria:
Inclusion Criteria:

* Patients with benign or malignant lesions of the pancreas
* Subjected to distal, central pancreatectomy or enucleations of the left pancreas
* Patients ASA (American Society of Anesthesiologists I-III
* Open or laparoscopic approach.

Exclusion Criteria:

* ASA ≥IV patients
* Patients with limitrophic or neuroendocrine lesions
WI-INTUIT: Bridging Community Based Continence Promotion and Primary Care

This project seeks to determine whether primary care practices that receive supplemental partnership building implement UI-Assist with higher fidelity than practices that receive streamlined practice facilitation alone.

This quality improvement research project is one of five across the country funded by the Agency for Healthcare Research and Quality (AHRQ) through the EvidenceNOW Managing Urinary Incontinence initiative titled: "Improving Nonsurgical Treatment of Urinary Incontinence among women in Primary Care." The purpose of this national initiative is to identify implementation strategies that best support primary care practices in delivering high quality care for urinary incontinence. Components of high-quality care including screening, diagnosing, and offering non-surgical first-line treatments for urinary incontinence in women, all of which already occur in primary care.

The WI-INTUIT quality improvement project compares two implementation strategies to implement UI-Assist, an intervention to support primary care practices in increasing their rates of screening, diagnosing, and treating urinary incontinence in their adult female patients: (1) streamlined practice facilitation (SPF) and (2) streamlined practice facilitation in combination with partnership building (SPF+PB).

Eligibility Criteria:
This is an organizational intervention. Outcomes will be evaluated at the population-level by facility.

Primary Care practices in Wisconsin serving female adults:

Inclusion Criteria:

* Patients must be 18 years or older and be assigned female at birth
* Practices must have and be willing to provide key data from electronic health records
* Practices willing to participate in partnership building activities (randomly allocated)
* Practices willing to work with a practice facilitator to implement UI-Assist in their practice

Exclusion Criteria:

- No additional exclusion criteria
Trunk Rehabilitation Compared to Core Stability in Patients With Multiple Sclerosis

BACKGROUND Balance, gait, community mobility, and risk of falls are often associated with trunk impairment among people with Multiple Sclerosis (PwMS). Consequently, there is a pressing need for interventions addressing these concerns and exploring the potential effects of trunk rehabilitation.

LONG-TERM GOAL Offering guidance for effective plan selection, potentially included in rehabilitation guidelines for PwMS.

HYPOTHESIS Trunk exercises performed in multiplanar movement on unstable surfaces incorporated with dual-tasks (DT) could improve the functional outcomes more than standard one-plane core stability exercises.

SPECIFIC AIMS Investigating the effectiveness of trunk rehabilitation in PwMS and determining the optimal intervention strategy.

METHODS 50 PwMS randomly assigned into two groups. Trunk Group received trunk exercises on unstable surfaces with DT training, while the Core Group underwent standard one-plane core stability exercises on stable surfaces without DT. Additionally, both received conventional treatment. Primary outcome was the trunk impairment scale (TIS). Secondary outcomes included the Berg balance scale (BBS), Timed Up and Go (TUG), Modified Falls Efficacy (FES), Modified Fatigue Impact Scale (MFIS), Hospital Anxiety and Depression Scale (HADS), and Reintegration to Normal Living Index (RNLI).

SIGNIFICANCE Enhancing our understanding of trunk exercises' benefits and providing valuable guidance to clinicians for choosing the optimal treatment plan.

There is a lack of comprehensive trunk rehabilitation protocols within the field of multiple sclerosis. The existing studies mostly focus on core stability, pelvic muscles, or alternative methods. Consequently, the aim was to develop a protocol to investigate the potential positive effects of trunk rehabilitation. Drawing from our review of relevant literature, investigators in this study have developed a trunk training protocol that focuses on multiplanar movements carried out on unstable surfaces and additionally, incorporated dual-task training (DT), which adds a layer of complexity.

Eligibility Criteria:
Inclusion Criteria:

* Clinically diagnosed with MS (McDonald's criteria)
* Able to walk 5 meters without assistance.
* No relapse in the past 2 months.

Exclusion Criteria:

* Recent surgery.
* Cognitive or psychological dysfunctions.
* Diagnosis of any other systematic disease.
Role of Anxio-depressive History on Return to Work and Sport After Rotator Cuff Surgery

Anxiety-depressive disorders are also very frequent, in the form of different pathologies that are often intertwined (prevalence of generalized anxiety disorders in 5% of the population, characterized depressive episodes in 5%, etc.).

And it is even more frequent in patients with a cuff tendinopathy (26% and 23% of depression and anxiety respectively). These 2 pathologies are therefore responsible for significant economic expenses.

It is in this context that the investigators' wish to carry out this study seems justified in order to better understand and therefore manage this problem, which is frequently encountered in daily practice and which would therefore allow better understanding and therefore better information for the patients concerned.


Eligibility Criteria:
Inclusion criteria:

* Major subject (≥ 18 years)
* Operated between January 2008 and September 2009 arthroscopically for a symptomatic supraspinatus tendon rupture, retracted in zone 1, resistant to medical treatment with a mobile shoulder, fatty degeneration of stage 2 or less with also a preserved subacromial space
* Subject not objecting to the reuse of their data for scientific research purposes.

Exclusion criteria:

- Subject having expressed his opposition to the reuse of his data for scientific research purposes.
Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma

RATIONALE: Diagnostic procedures, such as magnetic resonance imaging, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying magnetic resonance imaging in response to radiation therapy in patients with high grade glioma.

Detailed DescriptionOBJECTIVES:

I. To develop a multimodality statistical model to act as a surrogate marker scheme of early changes in high grade glioma patients undergoing radiation therapy, using conventional MRI, MR diffusion tensor imaging, perfusion, permeability, and spectroscopic imaging while incorporating the radiation dose calculations delivered locally and the results of a clinical questionnaire into the model.

II. To assess treatment response to tumor and normal tissue changes. OUTLINE: Patients undergo multimodality MRI imaging at baseline, weeks 1, 2, 3, 5, and 6, and then 4-6 weeks after completion of radiation therapy.

Eligibility Criteria:
Inclusion Criteria:

* Patients being treated for diagnosed with high grade glioma (WHO grade III or IV) at the University of Pennsylvania Medical Center who will be undergoing radiation therapy to the brain
* Patient or legal representative able to provide written informed consent
* Adult males and nonpregnant females

Exclusion Criteria:

* Vulnerable populations as specified (including pregnant patients, prisoners, patients with pacemakers or metallic implants)
* Patients with renal failure
* Patients with any condition considered a contraindication to MRI
Treatment Choices for Improving Adherence and Outcome

This study will determine the effectiveness of offering primary care patients their preferred treatment versus one that is less desirable in improving treatment adherence and outcome.

This study investigates whether offering primary care patients treatment that is congruent with their preferred first choice improves adherence and outcomes, in comparison to offering treatment that is not congruent with their preferred first choice. All subjects are offered a treatment with demonstrated efficacy, namely either the antidepressant medication escitalopram or Interpersonal Psychotherapy for 5 months. We hypothesize that patients who receive congruent treatment will be more likely to initiate treatment, adhere to treatment, and achieve depression remission.

Eligibility Criteria:
Inclusion Criteria:

* age 21-99
* English-speaking
* DSM-IV criteria for major depression

Exclusion Criteria:

* unable to give informed consent
* MMSE\<24
* DSM-IV diagnosis of bipolar disorder, psychotic disorder, current alcohol or substance abuse
* active suicide ideation
* aphasia
* acute or severe medical illness
* currently receiving either antidepressant medication or psychotherapy